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Parkinson’s disease is one of the most common neurodegenerative diseases. Animal
models have contributed a large part to our understanding and therapeutics developed
for treatment of PD. There are several more exhaustive reviews of literature that provide
the initiated insights into the specific models; however a novel synthesis of the basic
advantages and disadvantages of different models is much needed. Here we compare
both neurotoxin based and genetic models while suggesting some novel avenues in
PD modeling. We also highlight the problems faced and promises of all the mammalian
models with the hope of providing a framework for comparison of various systems.
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PARKINSON’S DISEASE—MODEL UTILIZATION FOR
THERAPEUTICS
Parkinson’s disease (PD) is a common neurodegenerative disorder, with cardinal features of
akinesia, bradykinesia, rigidity, and tremors (Rodriguez-Oroz et al., 2009). The neuropathological
hallmarks of PD are the loss of dopaminergic neurons in the SubstantiaNigra pars compacta (SNc)
and the formation of intra-neuronal proteinaceous inclusions, called Lewy Bodies (LBs). Loss of
neurons from other brain regions has also been observed in the later stages of the disease, such
as the cholinergic nucleus basalis of Meynert, many subnuclei in the thalamus and amygdala,
and the serotoninergic neurons of the raphe nucleus (Jellinger, 1991; Braak et al., 2000, 2003). In
most cases of PD, injury or environmental insult induced changes in the brain connectivity and
gene expression, with genetic factors contributing to the predisposition, are suspected to cause
the disease but in a smaller fraction of cases, between 10 and 20%, genes are known to be the
culprits for causation. Genetic defects in mitochondrial function (Winklhofer and Haass, 2010),
dysfunction of the ubiquitin-proteosome pathway (McNaught et al., 2001), and alterations of free
radical formation (Palacino et al., 2004) have been shown to play a role in familial PD. Studies have
reported increases in the sensitivity of mice with these defects to neurotoxins (Nieto et al., 2006;
Haque et al., 2012).
The use of animals to model different aspects of PD phenotype allows us the ability to study both
disease progression and explore possible treatments. While none of the currently available models
of PD completely phenocopy the disease but they have contributed extensively to our knowledge of
PD. So far experimental models have been of two major types: (A) Toxin models and (B) Genetic
models. An understanding of different PD models can enhance the ability of PD researcher to
employ appropriate models for their experiments.
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TOXIN BASED MODELS
These are based on neurotoxins which allow for testing of
nigrostrial DA neuron degeneration. Figure 1 summarizes major
toxin models.
6-OHDA
6-hydroxydopamine (6-OHDA), presented in Figure 1A. is a
selective neurotoxin that was first reported to cause lesions in
nigrostriatal DA neurons in rats (Ungerstedt, 1968) but has been
subsequently shown to work in other animals such as mice (da
FIGURE 1 | Comparison of major toxin models. (A) 6-OHDA, (B) MPTP, (C) Rotenone, (D) Paraquat, (E) Methamphetamine. MAO A, Monoamine oxidase A;
MAO B, Monamine Oxidase B; DAT, Dopaminergic Transporter; NAT, Noradrenergic Transporter; SNc, Substantia Nigra pars Compacta; VTA, Ventral tegmental area;
VMAT2, Vesicular Monoamine Transporter 2.
Conceição et al., 2010; Thiele et al., 2012). 6-OHDA accumulates
in the cytosol and promotes formation of hydrogen peroxide,
other reactive oxygen species and quinines by auto-oxidation
(Cohen, 1984; Simola et al., 2007). Down regulation of dopamine
synthesis in the lesioned striatum has also been observed with
the non-lesioned striatum compensating for this by increased
dopamine production (Del-Bel et al., 2014) 6-OHDA being
hydrophilic cannot cross the blood brain barrier and thus
administration is carried out by direct injection in the Substantia
Nigra pars Compacta (SNc), Medial Forebrain Bundle (MFB)
or striatum, depending on the rate at which lesion formation is
desired. Injection into the SNc,MFB causes DA neuronal death in
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less than 24 h (Jeon et al., 1995). Striatal injection causes death of
DA neurons over the course of 1–3 weeks. Injection of 6-OHDA
causes progressive retrograde neuronal degeneration in the SNc
and Ventral Tegmental Area (VTA) (Sauer and Oertel, 1994;
Przedborski et al., 1995). In addition to DA transporters, it also
targets noradrenergic transporters (Luthman et al., 1989). Thus,
in addition to inducing PD symptoms, 6-OHDA also causes
damage to other parts of the brain. The other disadvantage of 6-
OHDA is that production of LB-like inclusions is not seen (Dauer
and Przedborski, 2003). Behavioral wise, unilaterally lesioned
rodents show drug induced rotational behavior (Blandini et al.,
2008). Motor impairments are also observed, primarily due to
impairment of limbs contralateral to the hemisphere in which the
6-OHDA is administered (Simola et al., 2007).
MPTP
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
presented in Figure 1B. is a neurotoxin precursor of 1-
methyl-4-phenylpyridinium (MPP+), which causes damage
to the nigrostriatal DA pathway with a significant loss of DA
neurons in the striatum and SNc, more similar to that seen in
PD. MPTP susceptibility increases with age (Ovadia et al., 1995).
MPTP is converted to an intermediate 1-methyl-4-phenyl-2,3-
dihydropyridinium by the action of monoamine oxidase B in glial
cells. This intermediate is then oxidized toMPP+ (Jackson-Lewis
and Przedborski, 2007). MPP+ has a high affinity for the plasma
membrane dopamine transporter with comparatively lower
affinities for the norepinephrine and serotonin transporters
(Javitch et al., 1985). Once inside dopaminergic neurons,
MPP+ can be sequestrated into synaptosomal vesicles or be
concentrated within the mitochondria (Ramsay and Singer,
1986) utilizing mitochondrial transmembrane potential. In
the mitochondria, MPP+ blocks the electron transport chain
by inhibiting Mitochondrial Complex I (Varastet et al., 1994).
Due to rapid conversion of MPTP to MPP+, most chronic
treatments are actually serial acute insults (Jackson-Lewis and
Przedborski, 2007). Thus, a true chronic model would require
continuous delivery of MPTP using devices such as osmotic
pumps (Fornai et al., 2005). Rats have proven to be resistant
to MPTP induced toxicity (Riachi et al., 1990). The reason for
this resistance has been speculated to be because of differential
MPP+ sequestration (Schmidt and Ferger, 2001). While MPTP
produces the best results when used in monkeys including
formation of LB like inclusions (Kowall et al., 2000) taking into
account practical considerations, the MPTP mouse model is
more popular. MPTP causes greater damage to DA neurons
in the SNc than in VTA (Blesa et al., 2011, 2012). Recent
dopaminergic neuron characterisation has found a specific DA
subtype in the SNc is more vulnerable to MPTP (Poulin et al.,
2014). Also the degeneration of nerve terminals to the putamen
is higher than those to the caudate nucleus (Blesa et al., 2010).
This too resembles PD phenotype.
Mice treated with MPTP also do not show behavior typical
of PD, however alterations in motor movement are observed,
where significant dopaminergic neuron loss is present (Jackson-
Lewis and Przedborski, 2007). This model also has a significant
weakness of the lack of formation of LBs in mice. Care must
be taken to study the interaction of the drug tested with MPP+
before conclusions about its efficacy are drawn as some drugs
might reduce the oxidative stress induced by MPTP. Also the
conversion of MPTP to MPP+ includes an intermediate, which
is oxidized to MPP+, thus an antioxidant treatment protocol
might give good results by targeting this step without actually
preventing DA neuron loss but this remains to be tested. Use of
probenicid to competitively inhibit renal excretion of MPTP has
also been shown to increase SNc neuronal loss (Meredith et al.,
2002). MPTP has a big advantage because of its lipophylic nature
as it can cross the blood brain barrier, thus allowing greater ease
in administration, including systemic administration.
ROTENONE
Rotenone, presented in Figure 1C. occurs naturally in several
plants and has been used as a broad spectrum insecticide,
and pesticide. It functions by blocking the mitochondrial
electron transport chain through inhibition of complex I, as
seen in MPTP. Rotenone also blocks mitosis and inhibits cell
proliferation. This is by perturbation of microtubule assembly
and decreasing the GTP hydrolysis rate (Srivastava and Panda,
2007). Chronic systemic exposure to rotenone in rats causes
many features of PD, including nigrostriatal DA degeneration.
This model has been shown to reproduce almost all the
features of PD, including the formation of intracellular inclusions
that resemble LB (Sherer et al., 2003). Rotenone can be
injected intraperitoneally, intravenously or subcutaneously for
systemic treatment. It has also been directly injected into the
brain stereotaxically (Xiong et al., 2009). However, despite
demonstrating the slow and specific loss of DA neurons, this
model is difficult to replicate due to the high mortality observed
in rats, when treated with rotenone (Fleming et al., 2004).
Rotenone is highly lipophilic and easily crosses the blood brain
barrier (Talpade et al., 2000).
PARAQUAT
N,N′-dimethyl-4,4′-bipyridinium dichloride (Paraquat),
presented in Figure 1D. is one of the most widely used
herbicides. It shares structural similarity to MPP+. Parquat
causes oxidative stress in the cell through generation of
reactive oxygen species. It has been shown to cause SNc DA
neuron degeneration and like rotenone also induces formation
of LB in DA neurons in mice and rats (McCormack et al.,
2002; Cicchetti et al., 2005). However, large variability has
been observed in cell death and specificity for DA neurons
including some contradictions, with some researchers claiming
that Paraquat does not cause changes in the nigrostriatal DA
system (Miller, 2007). Paraquat has been used in conjuction
with 2-(dithiocarboxy)aminoethylcarbamodithioato(2-)-kS, kS’
manganese also called Maneb, a fungicide, which has been shown
to potentiate the effects of both MPTP and Paraquat. Maneb on
its own has also been shown to decrease locomotor activity and
produce SNc neurons loss (Thrash et al., 2007).
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AMPHETAMINE BASED MODELS
Treatment of rodents and primates with high doses of
methamphetamine has shown selective DA, serotonergic nerve
terminal as well as SNc neuronal loss (Wagner et al., 1979; Thrash
et al., 2009). Methamphetamine, presented in Figure 1E. causes
this damage by promoting change in the distribution of DA
from the synaptic vesicle to the cytosol (Howard et al., 2011).
To do so, it interacts with both the dopamine transporter (DAT)
and the vesicular monoamine transporter (VMAT2), resulting
in promoting the collapse of vesicular proton gradients. This
leads to DA oxidation within the neuronal cytosol, which causes
oxidative stress within the cell by generation of hydroxyl and
superoxide Reactive Oxygen Species (ROS) (Larsen et al., 2002;
Cadet et al., 2007). Subtoxic concentrations of methamphetamine
has been shown to protect DA neurons cells against 6-OHDA
toxicity, whereas higher concentrations of methamphetamine
exacerbated it (El Ayadi and Zigmond, 2011). On the other hand,
despite affectingmainly the serotonergic system,MDMA can also
affect DA neurons, with the repeated administration of MDMA
producing degeneration of DA terminals in the striatum, and
neuronal loss in the SNc (Granado et al., 2008a,b). Development
of an amphetamine model of PD, especially in conjunction
with other neurotoxins such as MPTP, and Paraquat might be
useful.
GENETIC MODELS
In theory genetic model of a simple disease or a syndrome can
be made of a mutant gene involved in the progression of the
disease in patients or even a gene that might not be validated to be
involved in patients but can recapitulate some key features of the
disease in the model system. The goal of making genetic model is
3-fold:
1. Understand the signaling and pathways associated with
known causal gene.
2. Understand disease signaling by introducing a perturbation in
signaling through a gene not found to be causal in patients
but canmimic key disease and equally importantly disease like
phenotypes.
3. To enable therapeutic screens.
Five genes are frequently targeted as disease models for PD
and they have all been known to have causal connection in
familial PD. One of the largest genome wide analysis studies
for PD to date has implicated 28 independent variants across
24 loci (Nalls et al., 2014). What is not obvious is whether the
genes encoded (Nalls et al., 2014) within these loci function as
the main drivers, carriers or helpers of disease progression. In
more common forms of PD, several gene functions are likely
to be altered, hence monogenic models are expected to be less
successful than toxin-induced models. That said genetic models
have been of use in modeling familial PD and also have shed
some light on more common PD mechanisms. Some of the
model organisms have been invertebrates and onemight be led to
question the utility of invertebrate models that do not have SNc.
While invertebrate models mimic more simplistic features such
as loss of DA neurons, they provide a good vehicle to understand
the genetic network, molecular signaling, and provide for first
round of screening that can be followed up with further work
in mammalian models. Tables 1–4 describe the various common
rodent genetic models for PD, while Table 5 details fruit fly
models. Some of the models are described below:
α-SYNUCLEIN
This gene is linked to a dominant type of familial PD and
the α-synuclein protein is a major part of LBs observed in
the brains of PD patients (Iwatsubo, 2003). Table 1 catalogs α-
synuclein mice models, while Table 4 has rat genetic models,
including α-synuclein. Mutations in five locations have so far
been identified in familial PD (Polymeropoulos et al., 1997;
Krüger et al., 1998; Singleton et al., 2003; Chartier-Harlin et al.,
2004; Zarranz et al., 2004; Appel-Cresswell et al., 2013; Kiely et al.,
2013; Proukakis et al., 2013). Injection of wild type or mutant α-
synucelin protein has been shown to induce loss of DA neurons,
and cause motor impairment in both mice and rats (Oliveras-
Salvá et al., 2013). Several mutant lines have been developed in
mice that show decreases in striatal DA, exhibit inclusion bodies,
and show motor impairmentsbut several fail to show significant
degeneration of nigrostrial PD neurons (Masliah, 2000; van der
Putten et al., 2000; Giasson et al., 2002; Lee et al., 2002; Richfield
et al., 2002; Gomez-Isla et al., 2003; Fernagut and Chesselet,
2004; Thiruchelvam et al., 2004; Tofaris et al., 2006; St Martin
et al., 2007; Nuber et al., 2008; Wakamatsu et al., 2008; Daher
et al., 2009). Recent use of the Pitx3 promoter shows promise
as the line shows progressive SNc DA neuronal loss too along
with decrease in DA release and significant motor defects (Li
et al., 2009a; Lin et al., 2012). Viral Vectors such as Lentiviruses,
Adeno-associated Viruses have been directly injected into the
brain at the SNc near the cell bodies of DA neurons in both
mice and rats (Lauwers et al., 2003, 2007). Mutant lines with
DA loss and inclusion bodies have also been developed in rats
(Klein et al., 2002; Lo Bianco et al., 2002; Yamada et al., 2004;
McFarland et al., 2009; Koprich et al., 2010; Oueslati et al., 2012;
Engeln et al., 2013). While so many models have been developed
with α-synuclein, its exact function is not known. Available data
suggests that α-synuclein might be a presynaptic regulator of
DA release, synthesis or storage, and has been shown to be a
regulator of paired-stimulus depression (PSD) (Maries et al.,
2003). It also seems to play a role in neuroprotection (Quilty et al.,
2006).
LRRK 2
Mutations to this gene are known to cause an autosomal
familial form of PD (Funayama et al., 2002; Paisán-Ruíz et al.,
2004). Mice LRRK2 lines are compared in Table 2 and rat
lines in Table 4. Mitochondrial dysfunction enhances LRRK2
neurodegeneration in somemodels through unclear mechanisms
(Winklhofer and Haass, 2010). LRRK 2 knockout mice have been
demonstrated to show abnormal aggregation and accumulation
of proteins including α-synuclein, while otherwise not showing
any nigrostriatal degeneration (Li et al., 2007, 2009b; Melrose
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TABLE 1 | α-synuclein models in mice.
α-synuclein in mouse model
Types Promoter SN neuron loss Inclusion bodies Motor impairment References
WT PDGF-β − + + Masliah, 2000
WT/A53T Thy1 − + + van der Putten et al., 2000
WT/A30P/A53T TH − − ND Matsuoka et al., 2001
WT Prp − − − Giasson et al., 2002
A53T Prp − + + Giasson et al., 2002
WT Prp − − − Lee et al., 2002
A30P Prp − + − Lee et al., 2002
A53T Prp − + + Lee et al., 2002
WT TH − − − Richfield et al., 2002
A53T and A30P TH + − + Thiruchelvam et al., 2004
A30P PrP − + + Gomez-Isla et al., 2003
WT/A30P/A53T CMV + + + Lauwers et al., 2003
WT (1–120) TH − + + Tofaris et al., 2006
WT CMV + − ND St Martin et al., 2007
WT CaMKII + − + Nuber et al., 2008
WT (1–130) TH + − + Wakamatsu et al., 2008
WT (1–119) ROSA26 − − ND Daher et al., 2009
A53T ROSA26 − − ND Daher et al., 2009
E46K ROSA26 − − ND Daher et al., 2009
A53T Pitx3 + − + Lin et al., 2012
WT/A53T CMVE- Syn 1 + + + Oliveras-Salvá et al., 2013
WT, Human α-synuclein; PDGF-β, Platelet Derived Growth Factor-β; Thy-1, Thy-1 Cell Surface Antigen; TH, Tyrosine Hydroxylase; Prp, Prion protein promoter; CMV, cytomegalovirus;
CaMKII, Calcium/calmodulin-dependent protein kinase II; ROSA26, ROSAβgeo26P locus; Pitx3, Paired-Like Homeodomain 3; CMVE- Syn 1, cytomegalovirus enhanced synapsin 1;
ND, No Data.
TABLE 2 | LRRK2 models in mice.
LRRK2 in mouse model
Types Promoter SN neuron loss Inclusion bodies Motor impairment References
R1441C/G* mLRRK2 ND ND ND Li et al., 2007
R1441C* mLRRK2 − − − Tong et al., 2009
WT# mLRRK2 − − + Li et al., 2009b
R1441G# mLRRK2 − − + Li et al., 2009b
WT# hLRRK2 − − − Melrose et al., 2010
G2019S# hLRRK2 − − − Melrose et al., 2010
exon 1* mLRRK2 − + ND Tong et al., 2010
exon 29, 30* mLRRK2 − + ND Tong et al., 2010
G2019S# CMVE- PDGFβ + (DA loss) − − Ramonet et al., 2011
R1441C# CMVE-PDGFβ − − + Ramonet et al., 2011
WT# CMVE-PDGFβ − − − Ramonet et al., 2011
G2019S# CMVE-PDGFβ + (DA loss) − + Chen et al., 2012
R1441C# ROSA26 − − − Tsika et al., 2014
mLRRK2, murine LRRK2; hLRRK2, human LRRK2; *mouse paralog, #human; WT, Wild Type; CMVE-PDGFβ, cytomegalovirus enhanced-platelet derived growth factor- β; ROSA26,
ROSAβgeo26P locus; ND, No Data.
et al., 2010; Tong et al., 2010; Ramonet et al., 2011; Hinkle
et al., 2012; Tsika et al., 2014). Virus based models have so
far shown some nigrostriatal degeneration however only partial
PD phenotypes have so far been developed (Dusonchet et al.,
2011; Chen et al., 2012). The LRRK2 gene codes for a 2527
amino acid long protein with multiple domains (Anand and
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TABLE 3 | Parkin, PINK1, and DJ-1 mice models.
Mouse model
Promoter SN neuron loss Inclusion bodies Motor impairment References
PARKIN MOUSE PARALOG
Exon 3 deletion − − − − Goldberg et al., 2003
Exon 3 deletion − − − + Itier et al., 2003
Exon 2 deletion − − − − Perez and Hastings, 2004
Exon 7 deletion − − − − Von Coelln et al., 2004
Exon 3 deletion − ND ND ND Palacino et al., 2004
Truncated, Q311X Slc6a3 + (DA loss) − + Lu et al., 2009
WT nse − ND ND Bian et al., 2012
PINK-1 MOUSE PARALOG
4–7 Exon mutation − − − − Kitada et al., 2007
DJ-1 MOUSE PARALOG
Exon 2 deletion − − − + Goldberg et al., 2005,
Exon 2 deletion − − ND ND Yamaguchi and Shen, 2007,
Exon 3–5 deletion − − ND − Kim et al., 2005
Exon 7 inactivation − − ND + Manning-Bog˘ et al., 2007
Exon 2–3 deletion − − ND − Andres-Mateos et al., 2007
Exon 2 deletion − − − + Chandran et al., 2008
Exon 1 stop − + ND − Rousseaux et al., 2012
WT, Wild Type; Slca6a3, Solute carrier family 6a3; nse, neuron specific enolase; ND, No Data.
Braithwaite, 2009). Of these domains, two enzymatic domains,
the kinase domain and the GTPase domain are of particular
interest. In addition multiple protein-protein interaction regions
suggest that LRRK may have a role as a major signaling complex
(Marín, 2006; Mata et al., 2006). More information on LRRK 2
interactions is needed.
PARKIN
Parkin mutations have been seen in cases of familial PD. Table 3
covers Parkin mice strains. Parkin is an integral ligase in the
ubiquitin proteosome system (Lücking et al., 2000). Most Parkin
transgenic rodents do not exhibit loss of DA neurons in the SNc
(Goldberg et al., 2003; Itier et al., 2003; Palacino et al., 2004;
Von Coelln et al., 2004; Perez and Palmiter, 2005; Lu et al.,
2009; Bian et al., 2012; Liu et al., 2013). Some recent transgenic
rodent models have demonstrated modest loss of DA neurons
(Kitada et al., 2009; Dave et al., 2014; Van Rompuy et al., 2014).
Popularadoption of these models awaits successful reproduction
of the results.
DJ-1
DJ-1 is molecular chaperone that under redox reductions
plays a role in inhibition of α-synuclein aggregate formation
(Shendelman et al., 2004). DJ-1 mutations are linked to
autosomal recessive, early onset PD and genetic models using
DJ-1 are cataloged in Table 3. Rat model of DJ-1 is presented in
Table 4. KO models of DJ-1 show decreased DA release in the
striatum but no loss of SNc DA neurons (Goldberg et al., 2005;
Andres-Mateos et al., 2007; Manning-Bog˘ et al., 2007; Yamaguchi
and Shen, 2007; Chandran et al., 2008). Hypersensitivity to
neurotoxins, such as MPTP, was also observed in DJ-1 deficient
mice (Kim et al., 2005). One new model, the DJ1-C57 mouse,
shows promise with dramatic unilateral loss of dopaminergic
(DA) neurons in the SNc that progresses to bilateral degeneration
of the nigrostriatal axis with aging and mild motor behavior
deficits (Rousseaux et al., 2012). If reproduced, this model
would be highly beneficial to study early onset PD. A transgenic
rat model of DJ-1 has also been produced, which exhibits
dopaminergic neuron loss and motor abnormalities (Dave et al.,
2014).
PINK1
Mutations in the PARK6 locus of PINK1 cause a form of early-
onset autosomal PD. Table 3 presents mice model of PINK1 and
Table 4 rat models. PINK1 codes for a mitochondrial kinase,
which recruits Parkin from the cytosol to the mitochondria,
increases the ubiquitination activity of Parkin, and induces
Parkin-mediated mitophagy (Lazarou et al., 2013). Since PINK1
and the Parkin function in the same pathway, the phenotypes
of PINK1 and Parkin KO mice are very similar. No significant
DA neuron abnormalities or LB formation have been observed
in PINK1 KO mice however mitochondrial functional defects
and increased sensitivity to oxidative stress were observed (Kim
et al., 2005; Kitada et al., 2007). Increased levels of α-synuclein
through overexpression in PINK1 KOmice results in DA loss but
no degeneration in the SNc (Oliveras-Salvá et al., 2013). PINK1
KO rats exhibiting DA loss and motor impairment have been
developed recently which more closely mimics PD phenotype
(Dave et al., 2014).
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TABLE 4 | Genetic models in rats.
Rat model
Types Promoter SN neuron loss Inclusion bodies Motor impairment References
HUMAN α-SYNUCLEIN
A30P BA + (DA loss) + ND Klein et al., 2002
WT CBA + + + Kirik et al., 2002
A53T CBA + + + Kirik et al., 2002
WT/A30P/A53T PGK + (DA loss) + ND Lo Bianco et al., 2002
WT CMV + (DA loss) − ND Yamada et al., 2004
WT, S129D, S129A CMV + (DA loss) + ND McFarland et al., 2009
A53T CBA + (DA loss) + ND Koprich et al., 2010
WT, S87A ND + (DA loss) + + Oueslati et al., 2012
S87E ND − + − Oueslati et al., 2012
WT SYN 1 + (DA loss) + + Engeln et al., 2013
HUMAN LRRK2
WT SYN 1 − − ND Dusonchet et al., 2011
G2019S SYN 1 + − ND Dusonchet et al., 2011
PARKIN RAT HOMOLOG
WT PGK − ND ND Liu et al., 2013
WT (KO -Exon 4) − − − − Dave et al., 2014
DJ-1 RAT HOMOLOG
WT (KO -Exon 5) − + (DA loss) − + Dave et al., 2014
PINK-1 RAT HOMOLOG
WT (KO -Exon 4) − + (DA loss) − + Dave et al., 2014
WT, Wild –Type; BA, beta actin; CBA, chicken beta actin; PGK, phosphoglycerate kinase; CMV, cytomegalovirus; SYN-1, synapsin I; ND, No Data.
NON-MAMMALIAN GENETIC MODELS OF
PD
Barring α-synuclein, most familial PD genes have at least one
drosophila homolog. This includes homologs of PINK1, Parkin,
DJ-1, and LRKK2 that have been presented in Table 5. Models
with human α-synuclein and LRRK2 have also been developed
(Feany and Bender, 2000; Auluck et al., 2002; Chen and Feany,
2005; Pesah et al., 2005; Periquet et al., 2007; Liu et al., 2008;
Ng et al., 2009). These transgenic flies show some of the traits of
familial PD, with well characterized loss of dopaminergic neurons
and motor impairment, except in the case of DJ-1 in which
only motor impairment has been observed in DJ-1 β partial
deletion (Greene et al., 2003; Pesah et al., 2004; Chen and Feany,
2005; Meulener et al., 2005; Park et al., 2005, 2006; Clark et al.,
2006; Lavara-Culebras and Paricio, 2007; Sang et al., 2007) D.
melanogaster transgenic models have also helped in elucidating
the role of DJ-1, Parkin and PINK1 in mitochondrial physiology
(Venderova et al., 2009; Cookson, 2012). Further the study of
interactions of human α-synuclein, LRRK2, Parkin, PINK1, and
DJ-1 genes has also been possible in the drosophila system (Hirth,
2010).
Like D. melanogaster, D. rerio homologs of most familial PD
genes have been discovered. Unlike the rodent and drosophila
genetic models of PD, comparatively less characterisation has
been carried out in D. rerio. Expression of human α-synuclein
and knockouts of Parkin, PINK1, DJ-1 and LRRK2 have been
generated, which show some success in mimicking symptoms of
familial PD (Park et al., 2006; Bretaud et al., 2007; Anichtchik
et al., 2008; Flinn et al., 2009; Fett et al., 2010; Sheng et al.,
2010; Milanese et al., 2012; Priyadarshini et al., 2013; O’Donnell
et al., 2014). Verification of the results and further behavioral
testing is required to establish these models for therapeutic
screens.
The advantages of transparency and complete cell lineage
information make C. elegans an interesting model for
neurodegenerative diseases. Homologs of human PD-related
proteins, including Parkin, LRRK2, PINK1 and DJ-1, have been
found in C. elegans (Springer et al., 2005; Sakaguchi-Nakashima
et al., 2007; Sämann et al., 2009; Kamp et al., 2010; Lee et al.,
2013; Chen et al., 2015). Transgenic models developed for these
genes have shown increase sensitivity to neurotoxins like MPTP
(Ved et al., 2005).
CONCLUSION
Both toxin and genetic based models have their advantages and
disadvantages. However, the use of the two in combination would
be quite beneficial. Thus, a multi gene modulated transgenic
model in combination with a reliable and effective neurotoxin
might allow us to model the PD phenotype better. Addition
of a miRNA or siRNA cocktail to the appropriate model
systems could potentially allow for the creation of a very robust
and accurate PD model showing all the symptoms of PD.
Development of primary cell culture models might allow for
mimicking slow development of PD cellular damage phenotype
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TABLE 5 | Genetic models in fruit flies.
Drosophila model
Types Driver DA neuron loss Inclusion bodies Motor impairment References
Human α-synuclein
WT/A30P/A53T elav-GAL 4 + + + Feany and Bender, 2000
WT/A30P/A53T elav-GAL 4 + + ND Auluck et al., 2002
WT elav-GAL 4 − + + Pesah et al., 2005
S129D elav-GAL 4 + + ND Chen and Feany, 2005
S129A elav-GAL 4 − + ND Chen and Feany, 2005
WT 71–82 removed elav-GAL 4 − − ND Periquet et al., 2007
WT 1–120 trunc. elav-GAL 4 + + ND Periquet et al., 2007
WT 1–78 trunc. elav-GAL 4 + + ND Periquet et al., 2007
Human LRRK2
WT elav-GAL 4 + ND + Liu et al., 2008
G2019S elav-GAL 4 + ND + Liu et al., 2008
I2020T elav-GAL 4 − − + Venderova et al., 2009
WT ddc-GAL4 − − Ng et al., 2009
G2019S ddc-GAL4 + + Ng et al., 2009
Y1699C ddc-GAL4 + + Ng et al., 2009
G2385R ddc-GAL4 + − Ng et al., 2009
PARKIN FLY HOMOLOG
p25 insertion (null) − − ND + Greene et al., 2003
P21 insertion (null) − − − + Pesah et al., 2004
Q311X/T240R ddc-GAL4 + − + Sang et al., 2007
DJ-1 FLY HOMOLOG
DJ-1β part deletion − − − + Park et al., 2005
DJ-1α null − − − ND Meulener et al., 2005
DJ-1β null − − − ND Meulener et al., 2005
DJ-1β null − − ND ND Menzies et al., 2005
DJ-1α RNAI − + ND − Lavara-Culebras and
Paricio, 2007
DJ-1β null − − ND − Lavara-Culebras and
Paricio, 2007
PINK-1 FLY HOMOLOG
Kinase domain − − ND + Clark et al., 2006
UTR + part of exon 1 − + ND + Park et al., 2006
WT, Wild-type; elav, Embryonic Lethal—Abnormal Vision; ddc, dopa decarboxylase; RNAI, RNA Interference; UTR, Untranslated Region; ND, No Data.
too, and be useful for drug discovery. In coming years, we expect
to see better models for both basic understanding of PD and also
for improved high-throughput drug-discovery.
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